Tear Film Innovations completes Series B funding

Tear Film Innovations has completed $8.5 million in Series B funding, the company announced in a press release.

Led by Visionary Ventures Fund and Bluestem Capital, the funding will be used as growth capital for the iLux evaporative dry eye system, which received 510(k) clearance from the FDA in December 2017 and provides targeted therapy to blocked meibomian glands through an in-office treatment.

“The early, enthusiastic response to the iLux system from both the ophthalmic and optometric sectors is very encouraging,” OSN Chief Medical Editor Richard L. Lindstrom, MD, a member of the Visionary Ventures Fund investment team, said in the release. “Dry eye continues to dominate the clinical and commercial landscape in eye care, and we are confident the iLux device will play a significant role moving forward.”

Tear Film Innovations has completed $8.5 million in Series B funding, the company announced in a press release.

Led by Visionary Ventures Fund and Bluestem Capital, the funding will be used as growth capital for the iLux evaporative dry eye system, which received 510(k) clearance from the FDA in December 2017 and provides targeted therapy to blocked meibomian glands through an in-office treatment.

“The early, enthusiastic response to the iLux system from both the ophthalmic and optometric sectors is very encouraging,” OSN Chief Medical Editor Richard L. Lindstrom, MD, a member of the Visionary Ventures Fund investment team, said in the release. “Dry eye continues to dominate the clinical and commercial landscape in eye care, and we are confident the iLux device will play a significant role moving forward.”